title: Who is at risk for occult cancer after venous thromboembolism?
authors.forename: M M J
authors.initials: MM
authors.lastname: Beckers
authors.forename: R E G
authors.initials: RE
authors.lastname: Schutgens
authors.forename: M H
authors.initials: MH
authors.lastname: Prins
authors.forename: D H
authors.initials: DH
authors.lastname: Biesma
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D014408:Biomarkers, Tumor / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D009426:Netherlands / Q000453:epidemiology; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013923:Thromboembolism / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D020246:Venous Thrombosis / Q000097:blood / Q000453:epidemiology / Q000209:etiology*
chemical_list: D014408:Biomarkers, Tumor; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D